Skip Navigation

Cardiovascular Research 2002 55(2):417; doi:10.1016/S0008-6363(02)00499-6
© 2002 by European Society of Cardiology
This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Störk, S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Störk, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2002, European Society of Cardiology

Response to Letter to the Editor

Stefan Störk*

Kardiologie, Medizinische Poliklinik der Julius-Maximillians-Universität Würzburg, Klinikstrasse 6-8, 97070 Würzburg, Germany

* Tel.: +49 931 201 7088; fax: +49 931 201 7124 s.stoerk{at}medizin.uni-wuerzburg.de

Received 29 May 2002; accepted 29 May 2002

We thank Drs Jilma and Jilma-Stohlawetz for their interesting comments on our study on MCP-1 lowering effects of HRT in postmenopausal women [1]. Their finding of lower MCP-1 levels in 38 premenopausal women compared to 58 men [2] confirmed data from Inadera et al. taken from a cohort of 405 Japanese healthy subjects [3]. Lower levels of MCP-1, depending on the phase in the menstrual cycle, were observed by Jilma et al. in a group of 18 women. This is of interest, but does not establish causality. Therefore, in our opinion, concluding "female sex hormones decrease MCP-1 levels" is not warranted based on data presented by Jilma et al. In our intervention study, in an appropiate population, we established causality: Hormone replacement therapy decreased levels of MCP-1. In hindsight, the data from Jilma et al. can be considered to be in line with our conclusion. Indeed, it will be interesting to see whether a synergistic effect of ACE-inhibition and estrogens can be discerned. Clearly, subgroups in our study were too small to draw conclusions in this regard.


   References
Top
 References
 

  1. Störk S., Baumann K., von Schacky C., Angerer P. The effect of 17beta-estradiol on MCP-1 serum levels in postmenopausal women. Cardiovasc Res (2002) 53:642–649.[Abstract/Free Full Text]
  2. Jilma-Stohlawetz P., Homoncik M., Drucker C., Marsik C., Rot A., Mayr W.R., Seibold B., Jilma B. Fy phenotype and gender determine plasma levels of monocyte chemotactic protein. Transfusion (2001) 41:378–381.[CrossRef][Web of Science][Medline]
  3. Inadera H., Egashira K., Takemoto M., Ouchi Y., Matsushima K. Increase in circulation levels of monocyte chemoattractant protein-1 with aging. J Interferon Cytokine Res (1999) 19:1179–1182.[CrossRef][Web of Science][Medline]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Störk, S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Störk, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?